UMIN-CTR Clinical Trial

Public title

Examination of the effects of sauna bathing with the personal sauna "KUU" on body temperature, peripheral blood flow, skin condition, autonomic nerves and QOL

Acronym

Examination of the effects of sauna bathing with the personal sauna "KUU" on body temperature, peripheral blood flow, skin condition, autonomic nerves and QOL

Scientific Title

Examination of the effects of sauna bathing with the personal sauna "KUU" on body temperature, peripheral blood flow, skin condition, autonomic nerves and QOL

Scientific Title:Acronym

Examination of the effects of sauna bathing with the personal sauna "KUU" on body temperature, peripheral blood flow, skin condition, autonomic nerves and QOL

Region

Japan

Condition

No

Classification by specialty

Not applicable

Adult

Classification by malignancy

Others

Genomic information

NO

Narrative objectives1

This test is to examine the effects of sauna bathing on body temperature, peripheral blood flow, skin condition, autonomic nerves and QOL by using the test product (personal sauna "KUU").

Basic objectives2

Safety,Efficacy

Basic objectives -Others

Trial characteristics_1

Trial characteristics_2

Developmental phase

Primary outcomes

Indexes for effectiveness(Weight/body fat percentage/BMI(1), Salivary amylase(1), Sublingual thermometry(2), Blood flow measurement with TOKU Capillaro(3), Skin surface temperature measurement with thermography(4), Autonomic nerve function(1), Image analysis by VISIA(1), Skin moisture content(1), Japanese version of the UWIST Mood Checklist(5), St. Mary's Hospital Sleep Questionnaire(6) and Visual Analogue Scale(6).)

(1) Before sauna bath and after 30 minutes of 2 sets of sauna bath.
(2) Before sauna bath, during outside air bath (2 times), immediately after 2 sets of sauna baths, after 30 minutes of 2 sets of sauna bath.
(3) Before sauna bath, immediately after 2 sets of sauna baths, after 30 minutes of 2 sets of sauna bath.
(4) Before sauna bath and immediately after 2 sets of sauna baths.
(5) Before sauna bath, after 30 minutes of 2 sets of sauna bath and when waking up the next day.
(6) Before sauna bath and when waking up the next day.

Key secondary outcomes

*Safety
[1] Blood pressure, pulsation.
[2] Doctor's questions.
[3] Adverse events: number of cases and expression rate of adverse events.
(1)Before sauna bath and after 30 minutes of 2 sets of sauna bath.
(2) After 30 minutes of 2 sets of sauna bath.

Study type

Interventional

Basic design

Single arm

Randomization

Non-randomized

Randomization unit

Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification

Dynamic allocation

Institution consideration

Blocking

Concealment

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Device,equipment

Other

Interventions/Control_1

Single use of test product (2 sets of 8 minutes sauna, 1 minute water bath, and 5 minutes outside air bath)

Interventions/Control_2

Interventions/Control_3

Interventions/Control_4

Interventions/Control_5

Interventions/Control_6

Interventions/Control_7

Interventions/Control_8

Interventions/Control_9

Interventions/Control_10

Age-lower limit

20

years-old

<=

Age-upper limit

60

years-old

>

Gender

Female

Key inclusion criteria

[1] Healthy Japanese females aged 20-59 years.
[2] Individuals who are healthy and have no chronic physical disease including skin disease.
[3] Individuals whose written informed consent has been obtained after explanation of this study.
[4] Individuals who can have an examination on a designated check day
[5]Individuals judged appropriate for the study by the principal.

Key exclusion criteria

[1] Individuals using medical products.
[2] Individuals who are patient or have a history of psychiatric disease, high blood pressure, diabetes, and hyperlipidemia.
[3] Individuals who have had a bad physical condition in the sauna bath in the past.
[4] Individuals with strange skin conditions at measurement points.
[5] Individuals with strange skin conditions at measurement points.
[6] Individuals who used a drug to treat a disease in the past 1 month (except temporal usage for pollenosis).
[7] Individuals who have a history of serious hepatopathy, kidney damage, heart disease, hematological and blood disease.
[8] Individuals who contract or have a history of serious gastrointestinal disease.
[9] Individuals with serious anemia.
[10] Individuals whose BMI is over 30 kg/m2.
[11] Individuals who are a smoker.
[12] Individuals who have a habit of using sauna now or within the past 3 months.
[13] Individuals who have a habit to use drug claiming to improve skin condition in the past 3 months.
[14] Individuals who have a habit to ingest health-promoting foods, or supplements containing similar composition with a test food in the past 3 months or will ingest those foods during the test period.
[15] Individuals who have a habit to use Foods with Function Claims, functional foods and/or supplements claiming to improve cold sensitivity, blood flow, blood pressure, and thermal comfort effect in the past 3 months and/or are planning to use those foods during test periods.
[16] Individuals who excessively take alcohol (expressed in an amount of alcohol: over 30mg/day).
[17] Individuals whose observation date is menstrual
[18] Individuals who had been conducted an operation or beauty treatment on the test spot.
[19] Individuals who are or are possibly pregnant, or are lactating.
[20] Individuals who participated in other clinical studies in the past 3 months.
[21] Individuals judged inappropriate for the study by the principal.

Target sample size

10

Name of lead principal investigator

1st name	Yukinobu
Middle name
Last name	Shimamoto

Organization

CloudNine Inc.

Division name

Representative director

Zip code

730-0051

Address

1F Building Hirotake Otemachi, 2-2-9 Otemachi, Naka-ku, Hiroshima City, Hiroshima 730-0051, JAPAN

TEL

+81-82-545-5488

Email

shimamoto@cloud9-japan.com

Name of contact person

1st name	Ryoma
Middle name
Last name	Shimizu

Organization

TES Holdings Co., Ltd.

Division name

Administrative Department of Clinical Trials

Zip code

110-0015

Address

6F Kairaku Building 2-7-5 Higashiueno Taito-ku Tokyo 110-0015, JAPAN

TEL

+81-3-6801-8480

Homepage URL

Email

r.shimizu@tes-h.co.jp

Institute

TES Holdings Co., Ltd.

Institute

Department

Personal name

Organization

CloudNine Inc.

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization

Co-sponsor

Name of secondary funder(s)

Organization

Ueno-Asagao Clinic Ethical Review Committee

Address

6F Kairaku Building 2-7-5 Higashiueno Taito-ku Tokyo 110-0015, JAPAN

Tel

+81-3-6240-1162

Email

i.takahashi@tes-h.co.jp

Secondary IDs

NO

Study ID_1

Org. issuing International ID_1

Study ID_2

Org. issuing International ID_2

IND to MHLW

Institutions

Date of disclosure of the study information

2022

Year

05

Month

12

Day

URL releasing protocol

Publication of results

Unpublished

URL related to results and publications

Number of participants that the trial has enrolled

Results

Results date posted

Results Delayed

Results Delay Reason

Date of the first journal publication of results

Baseline Characteristics

Participant flow

Adverse events

Outcome measures

Plan to share IPD

IPD sharing Plan description

Recruitment status

Completed

Date of protocol fixation

2022

Year

05

Month

06

Day

Date of IRB

2022

Year

05

Month

09

Day

Anticipated trial start date

2022

Year

05

Month

17

Day

Last follow-up date

2022

Year

05

Month

18

Day

Date of closure to data entry

Date trial data considered complete

Date analysis concluded

Other related information

Registered date

2022

Year

05

Month

12

Day

Last modified on

2022

Year

11

Month

18

Day

Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000054402